159 related articles for article (PubMed ID: 27329924)
1. First-Line Atezolizumab Effective in Bladder Cancer.
Cancer Discov; 2016 Aug; 6(8):OF7. PubMed ID: 27329924
[TBL] [Abstract][Full Text] [Related]
2. Atezolizumab in invasive and metastatic urothelial carcinoma.
Crist M; Balar A
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1295-1301. PubMed ID: 28994323
[TBL] [Abstract][Full Text] [Related]
3. Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.
Inman BA; Longo TA; Ramalingam S; Harrison MR
Clin Cancer Res; 2017 Apr; 23(8):1886-1890. PubMed ID: 27903674
[TBL] [Abstract][Full Text] [Related]
4. [Atezolizumab (Tecentriq
Bernard-Tessier A; Bonnet C; Lavaud P; Gizzi M; Loriot Y; Massard C
Bull Cancer; 2018 Feb; 105(2):140-145. PubMed ID: 29290331
[TBL] [Abstract][Full Text] [Related]
5. Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers.
Krishnamurthy A; Jimeno A
Drugs Today (Barc); 2017 Apr; 53(4):217-237. PubMed ID: 28492290
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
7. [Advanced bladder cancer : From chemo- to immunotherapy].
Horn T; Krege S; Retz M
Urologe A; 2018 Jun; 57(6):686-692. PubMed ID: 29637216
[TBL] [Abstract][Full Text] [Related]
8. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Powles T; Durán I; van der Heijden MS; Loriot Y; Vogelzang NJ; De Giorgi U; Oudard S; Retz MM; Castellano D; Bamias A; Fléchon A; Gravis G; Hussain S; Takano T; Leng N; Kadel EE; Banchereau R; Hegde PS; Mariathasan S; Cui N; Shen X; Derleth CL; Green MC; Ravaud A
Lancet; 2018 Feb; 391(10122):748-757. PubMed ID: 29268948
[TBL] [Abstract][Full Text] [Related]
9. Atezolizumab in urothelial bladder carcinoma.
Hamilou Z; Lavaud P; Loriot Y
Future Oncol; 2018 Feb; 14(4):331-341. PubMed ID: 29135284
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises.
Aragon-Ching JB; Trump DL
Future Oncol; 2016 Sep; 12(17):2049-58. PubMed ID: 27306417
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma.
Patel R; Bock M; Polotti CF; Elsamra S
Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):225-232. PubMed ID: 28043166
[TBL] [Abstract][Full Text] [Related]
12. First Anti-PD-L1 Drug Approved for NSCLC.
Cancer Discov; 2016 Dec; 6(12):OF1. PubMed ID: 27920140
[TBL] [Abstract][Full Text] [Related]
13. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
[TBL] [Abstract][Full Text] [Related]
14. Spotlight on atezolizumab and its potential as an oncology agent.
Redman JM; Madan RA
Expert Rev Anticancer Ther; 2018 Aug; 18(8):719-722. PubMed ID: 29877103
[No Abstract] [Full Text] [Related]
15. The Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma.
Gwynn ME; DeRemer DL
Ann Pharmacother; 2018 Jan; 52(1):60-68. PubMed ID: 28831813
[TBL] [Abstract][Full Text] [Related]
16. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.
Passiglia F; Galvano A; Rizzo S; Incorvaia L; Listì A; Bazan V; Russo A
Int J Cancer; 2018 Mar; 142(6):1277-1284. PubMed ID: 29080213
[TBL] [Abstract][Full Text] [Related]
17. Durvalumab for the treatment of urothelial carcinoma.
Alsharedi M; Srivastava R; Elmsherghi N
Drugs Today (Barc); 2017 Dec; 53(12):647-652. PubMed ID: 29517083
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab for the treatment of bladder cancer.
Hakenberg OW
Expert Opin Biol Ther; 2017 Oct; 17(10):1309-1315. PubMed ID: 28737430
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
[TBL] [Abstract][Full Text] [Related]
20. Anti-PD-L1 antibody active in metastatic bladder cancer.
Brower V
Lancet Oncol; 2015 Jan; 16(1):e11. PubMed ID: 25638546
[No Abstract] [Full Text] [Related]
[Next] [New Search]
